IDT Australia Limited · ASX:IDT

IDT Australia — H1 FY2022 Earnings Presentation

8 slides from IDT Australia's earnings presentation, Feb 23, 2022

  1. Slide 1: 2022 Interim Results and Investor Update

    IDT AUSTRALIA LIMITED 2022 INTERIM RESULTS AND INVESTOR UPDATE FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 23 February 2022

  2. Slide 2: Key Operational Highlights

    Key Operational Highlights IDT Maintaining Profitability, Strong Cash Balance  H1 FY`22: Revenue year-on-year increase of 74% to $8.56 million, EBITDA of $1.97 million and $1.21 million Profit  H1 FY`22 closing cash balance of $13.31 million Sterile Manufacturing Licence Secured From The Therapeut

  3. Slide 3: Key Financial Highlights

    Key Financial Highlights Strong cash balance of $13.31 million Half Year ended 31 December (‘$000) 2021 2020 Variance Year-on-year Revenue increase of 74% to $8.56 million Positive EBITDA of $1.97 million achieved for the half Revenue 8,559 4,911 3,648 74% year $1.21 million Profit for the half year

  4. Slide 4: Sterile Manufacturing: Australia's First cGMP mRNA Drug Product

    Sterile Manufacturing: Australia’s First cGMP mRNA Drug Product  During the Half Year in review IDT engaged with the Therapeutic Goods Administration (TGA) to successfully deliver the Sterile Readiness Letter Agreement finalised with the Australian Government, Department of Health  A Sterile Manuf

  5. Slide 5: Sovereign Manufacturing

    Sovereign Manufacturing Approach-To-Market Bid Unsuccessful Modern Manufacturing Initiative Bids Remain Live  IDT put forward its existing and licenced sterile manufacturing facility in support of a submission to the Australian Government’s Onshore mRNA Manufacturing Capability: Approach To Market

  6. Slide 6: Medicinal Cannabis

    Medicinal Cannabis IDT making further progress executing on its Medicinal Cannabis Manufacturing Plan  IDT continues to progress the cGMP development of a range of proprietary medicinal cannabis active pharmaceutical ingredient and finished dosage form products  Stability programs ongoing for IDT’

  7. Slide 7: IDT Australia Limited Board and Executive Team

    IDT Australia Limited Board of Directors Executive Team Mr Alan Fisher Chair Dr David Sparling CEO Experienced corporate advisor and public company director with a proven More than 20 years of pharma and diagnostics experience in CEO, Director and track record of implementing strategies that enhance

  8. Slide 8: Disclaimer

    DISCLAIMER This presentation contains forward looking statements which involve known and unknown risks. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors which could cause actualresults and devel

IDT Australia — H1 FY2022 Earnings Presentation on 6ix